Effect of Concomitant Use of Montelukast and Efavirenz on Neuropsychiatric Adverse Events

Annals of Pharmacotherapy

Volumn 48, Issue 1, 2014, Pages 145-148

  Ibarra Barrueta, Olatz ^a   Palacios Zabalza, Itziar ^a   Mora Atorrasagasti, Oihana ^a   Mayo Suarez, Jose ^a  

^a HOSPITAL DE GALDAKAO   (Spain)

Author keywords

adverse reactions; efavirenz; montelukast; neuropsychiatric symptoms

Indexed keywords

CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; EFAVIRENZ; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ISOENZYME; MONTELUKAST;

ADULT; ARTICLE; ASTHMA; CASE REPORT; CONCENTRATION LOSS; CONFUSION; DISEASE EXACERBATION; DRUG METABOLISM; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IRRITABILITY; KARCH LASAGNA SCALE; MOOD DISORDER; NIGHTMARE; PRIORITY JOURNAL; RATING SCALE; SLEEP DISORDER; SYMPTOMATOLOGY; VIVID DREAM;

ADVERSE REACTIONS; EFAVIRENZ; MONTELUKAST; NEUROPSYCHIATRIC SYMPTOMS;

ACETATES; ADULT; ANTI-ASTHMATIC AGENTS; ANTI-HIV AGENTS; ASTHMA; BENZOXAZINES; DRUG INTERACTIONS; FEMALE; HIV INFECTIONS; HUMANS; NEUROTOXICITY SYNDROMES; QUINOLINES;

EID: 84892879094     PISSN: 10600280     EISSN: 15426270     Source Type: Journal    
DOI: 10.1177/1060028013510396     Document Type: Article

References (15)

1. Cooper V,Gellaitry G,Hankins M,Fisher M,Horne R.The influence of symptom experiences and attributions on adherence to highly active antiretroviral therapy (HAART): a six-month prospective, follow-up study.AIDS Care. 2009;21:520-528.
2. Maggiolo F.Efavirenz: a decade of clinical experience in the treatment of HIV.J Antimicrob Chemother. 2009;64:910-928.
3. Leutscher PD,Stecher C,Storgaard M,Larsen CS.Discontinuation of efavirenz therapy in HIV patients due to neuropsychiatric adverse effects.Scand J Infect Dis. 2013;45:645-651.
4. Foster City, CA: Bristol-Myers Squibb and Gilead Sciences, LLC; 2013:.
5. Marais S,Wilkinson RJ,Pepper DJ,Meintjes G.Management of patients with the immune reconstitution inflammatory syndrome.Curr HIV/AIDS Rep. 2009;6:162-171.
6. Whitehouse Station, NJ: Merck & Co., Inc; 2013:.
7. Kenedi CA,Goforth HW.A systematic review of the psychiatric side-effects of efavirenz.AIDS Behav. 2011;15:1803-1818.
8. Garcia GarciaMAguirreC. Montelukast: notificación de reacciones psiquiátricas en niños (abstract 6). Gac Med Bilbao. 2012;109:31. http://zl.elsevier.es/es/revista/gaceta-medica-bilbao-316/sumario/vol-109-num-01-13012838. Accessed October 20, 2013.
9. Philip G,Hustad C,Noonan G, et al.Reports of suicidality in clinical trials of montelukast.J Allergy Clin Immunol. 2009;124:691.e6-696.e6.
10. US Food and Drug Administration. Updated information on leukotriene inhibitors: montelukast (marketed as Singulair), zafirlukast (marketed as Accolate), and zileuton (marketed as Zyflo and Zyflo CR). Postmarket drug safety information for patients and providers. June12, 2009. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm165489.htm. Accessed May 24, 2013.
11. Schumock GT,Lee TA,Joo MJ,Valuck RJ,Stayner LT,Gibbons RD.Association between leukotriene-modifying agents and suicide: what is the evidence?.Drug Saf. 2011;34:533-544.
12. Montelukast: psychiatric disorders. Prescrire Int. 2012;21(123):15. http://english.prescrire.org/en/SummaryDetail.aspx?IssueId=123. Accessed October 20, 2013.
13. Naranjo CA,Busto U,Sellers EM, et al.A method for estimating the probability of adverse drug reactions.Clin Pharmacol Ther. 1981;30:239-245.
14. Aguirre C,Haramburu F.Official systems of pharmacovigilance in France and in Spain. Comparison of spontaneous reporting in two regional centers: Pays Basque and Bordeaux.Therapie. 1995;50:563-569.
15. Horn JR,Hansten PD,Chan LN.Proposal for a new tool to evaluate drug interaction cases.Ann Pharmacother. 2007;41:674-680.